We are live on ! Find out more
THC icon

Tenet Healthcare

253 hedge funds and large institutions have $3.57B invested in Tenet Healthcare in 2018 Q2 according to their latest regulatory filings, with 54 funds opening new positions, 77 increasing their positions, 86 reducing their positions, and 32 closing their positions.

New
Increased
Maintained
Reduced
Closed

136% more call options, than puts

Call options by funds: $217M | Put options by funds: $92.1M

69% more first-time investments, than exits

New positions opened: 54 | Existing positions closed: 32

31% more capital invested

Capital invested by funds: $2.72B → $3.57B (+$854M)

14% more funds holding in top 10

Funds holding in top 10: 78 (+1)

9% more funds holding

Funds holding: 233253 (+20)

6.56% less ownership

Funds ownership: 110.78%104.22% (-6.6%)

10% less repeat investments, than reductions

Existing positions increased: 77 | Existing positions reduced: 86

Holders
253
Holders Change
+20
Holders Change %
+8.58%
% of All Funds
5.79%
Holding in Top 10
8
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+14.29%
% of All Funds
0.18%
New
54
Increased
77
Reduced
86
Closed
32
Calls
$217M
Puts
$92.1M
Net Calls
+$125M
Net Calls Change
+$29.7M
Name Holding Trade Value Shares
Change
Change in
Stake
GCM
1
Glenview Capital Management
New York
$601M
BlackRock
2
BlackRock
New York
$523M +$8.44M +271,527 +2%
Vanguard Group
3
Vanguard Group
Pennsylvania
$353M +$55.7M +1,793,023 +21%
Harris Associates
4
Harris Associates
Illinois
$247M -$3.42M -110,125 -1%
PHS
5
PFM Health Sciences
California
$146M +$24.5M +786,785 +22%
DKCM
6
Davidson Kempner Capital Management
New York
$117M -$11M -352,893 -9%
State Street
7
State Street
Massachusetts
$100M -$321K -10,323 -0.3%
Dimensional Fund Advisors
8
Dimensional Fund Advisors
Texas
$79.1M +$3.31M +106,461 +5%
CCM
9
Camber Capital Management
Massachusetts
$75.5M -$62.2M -2,000,000 -47%
SCM
10
Scopia Capital Management
New York
$62.3M -$4.42M -142,274 -7%
Prudential Financial
11
Prudential Financial
New Jersey
$62.2M +$49.3M +1,586,340 +594%
LBA
12
Letko, Brosseau & Associates
Quebec, Canada
$61.6M -$3.94M -126,630 -6%
JP Morgan Chase
13
JP Morgan Chase
New York
$56.1M +$13.1M +420,609 +34%
NCM
14
Nantahala Capital Management
Connecticut
$53.9M -$1.69M -54,375 -3%
Norges Bank
15
Norges Bank
Norway
$46M +$3.8M +122,252 +10%
Northern Trust
16
Northern Trust
Illinois
$45.6M +$1.97M +63,453 +5%
Morgan Stanley
17
Morgan Stanley
New York
$39.2M +$22.6M +727,713 +165%
PPA
18
Parametric Portfolio Associates
Washington
$37.9M +$4.37M +140,572 +14%
CCI
19
Columbus Circle Investors
$36.4M -$5.25M -168,769 -13%
Bank of New York Mellon
20
Bank of New York Mellon
New York
$32.6M -$345K -11,101 -1%
Goldman Sachs
21
Goldman Sachs
New York
$31.4M -$48.9M -1,572,107 -63%
Fidelity Investments
22
Fidelity Investments
Massachusetts
$29.5M -$11.2M -360,936 -29%
Charles Schwab
23
Charles Schwab
California
$26.7M +$3.89M +125,117 +19%
Geode Capital Management
24
Geode Capital Management
Massachusetts
$25.3M +$2.16M +69,522 +10%
RCM
25
Redwood Capital Management
New York
$21.6M -$8.78M -282,523 -31%

THC Hedge Fund Activity: Q2 2018 in Review

253 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Tenet Healthcare (THC) for Q2 2018, worth a combined $3.57B — up 31% from $2.72B a quarter earlier.

Buyers outnumbered sellers: 54 funds opened new THC positions and 32 closed out — a net gain of 22 holders — while 77 added to existing stakes and 86 trimmed.

The largest buyer was Vanguard Group, adding an estimated $55.7M. The largest seller was OrbiMed, cutting an estimated $119M.

  • 253 institutional investors held Tenet Healthcare (THC) as of Q2 2018, up from 233 in Q1 2018.
  • Funds reported $3.57B of Tenet Healthcare stock for Q2 2018, up 31% quarter-over-quarter.
  • 54 funds opened new Tenet Healthcare positions in Q2 2018 and 32 closed out, a net change of +22 holders.
  • The largest Tenet Healthcare buyer in Q2 2018 was Vanguard Group, an estimated $55.7M added.
  • The largest Tenet Healthcare seller in Q2 2018 was OrbiMed, an estimated $119M sold.

Based on aggregated 13F filings for Q2 2018.